Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
114.47
+3.96 (3.58%)
At close: Aug 14, 2026, 4:00 PM EDT
115.54
+1.07 (0.93%)
Pre-market: Aug 17, 2026, 5:32 AM EDT
Corcept Therapeutics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Corcept Therapeutics stock has a consensus rating of "Buy" and an average price target of $135.25. The average 1-year stock price forecast is 18.15% higher than the current stock price, while the lowest is $50 (-56.32%) and the highest is $165 (+44.14%).
Price Target: $135.25 (+18.15%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 6 | 6 | 6 | 6 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $161 | Buy | Reiterates | $161 | +40.65% | Aug 13, 2026 |
| Wolfe Research | Wolfe Research | Sell Maintains $50 | Sell | Maintains | $50 | -56.32% | Jul 30, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $88 → $165 | Buy | Reiterates | $88 → $165 | +44.14% | Jul 30, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $95 → $165 | Buy | Reiterates | $95 → $165 | +44.14% | Jul 30, 2026 |
| UBS | UBS | Buy Upgrades $72 | Buy | Upgrades | $72 | -37.10% | May 13, 2026 |
Financial Forecast
Revenue This Year
1.15B
from 761.41M
Increased by 50.63%
Revenue Next Year
1.76B
from 1.15B
Increased by 53.62%
EPS This Year
2.13
from 0.82
Increased by 160.16%
EPS Next Year
4.52
from 2.13
Increased by 111.72%
EPS and Forward PE are based on non-GAAP adjusted numbers.